Genuone Sciences Core Competencies
Learn MoreCDMO Specialized Capabilities
- CDMO Specialized Capabilities
- South Korea’s leading pharmaceutical CDMO company, Genuone Sciences is recognized for our talented professionals, highly efficient production facilities, expertise in manufacturing technology and systematic quality management. We provide total solutions tailored to customer needs with comprehensive medicine development skills and years of deep experience, from research and clinical to licensing and production processes.
Specialized R&D Services
- Specialized R&D Services
- We are currently launching new drug formulation production technologies as well as new drug delivery solutions. Our internationally established R&D capabilities and state-of-the-art research equipment make us a trusted partner of domestic pharmaceutical companies. We lead the Korean pharmaceutical industry.
Quality Production Capabilities
- Quality Production Capabilities
- Our production, high-quality management systems and top-performing manufacturing facilities are certified by South Korea’s Ministry of Food and Drug Safety (MFDS).
Production process efficiency research, as well as reliable supply chain management (SCM) across manufacturing, quality control and distribution, further speeds our ability to deliver high-quality products.
Formulation Development &
Production Capacities- Formulation Development & Production Capacities
- As an expert in a wide range of formulations, we develop products to specific customer requirements. And as the first and only Pharmaceutical CDMO in the nation with proprietary technology to produce Lidcap® (Lliquid-filled hard gelatin capsules), , we provide advanced differentiated services in research and processes.
PR Video
Media News
GENUONE Sciences Holds Genuone Customer Day to Mark its Third Anniversary
2023.11.16- ◼︎ Held its first corporate event with partners at the 63 Convention Center on the 15th, with 100 major partners across 50 departments in attendance ◼︎ Created a space for communication by sharing major industry news conducted by outside lecturers and networking with partner companies ◼︎ GENUONE announces investment and management plans for 2024, with plans to increase productivity by investing KRW 23.8 billion in large-capacity facilities ▲ On the 15th November, GENUONE hosted the Genuone Customer Day, inviting partnering companies to mark its third anniversary (Image provided by GENUONE Sciences) (2023-11-16)On November 16th, GENUONE Sciences (CEO Lee Sam-soo, hereinafter GENUONE), Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization), announced that the company had held a Genuone Customer Day to mark its third anniversary. On the 15th November, GENUONE invited some 100 major partners from across 50 departments to the 63 Convention Center in Yeouido, Seoul. The event was the first of its kind since the launch of GENUONE and was held to express gratitude to partner companies that have continued to cooperate with GENUONE and to share views on the current status of the industry. On this day, GENUONE invited external lecturers to share insights into the current status of the industry. Experts in each field gave lectures on unregistered patents and prospects of pharmaceutical pricing as a result of changes in the external environment with closing opportunities offered for networking. At the event, GENUONE also announced plans to expand production capacity through facility investment worth about KRW 23.8 billion in 2024. With such significant investment, GENUONE seeks to increase production volume and quality in order to offer improved services and encourage win-win collaborations. GENUONE already made an investment of KRW 12.5 billion last year to upgrade its production capacity. The additional investment of KRW 23.8 billion was largely driven by IMM PE, the shareholder company, to actively innovate GENUONE’s management and improve efficiency. Based on this investment, the company will make further efforts to increase production efficiency. “This first partner’s event was prepared for our partners, who have been with us for a long time. We wanted to create a place for communication so that we can grow together, share our futures, and build more than just a business relationship,” said Lee Sam-soo, CEO of GENUONE. He added, “We will step up our efforts to strengthen quality and expand production in order to take off as a global CDMO company. We will also continue to cooperate with our partners, and strengthen our competitiveness in the future”.
“Seeking Growth Through Increased Production” GENUONE Sciences Makes Additional Investment of KRW 23.8 Billion to Expand Facilities and Increase Production Efficiency
2023.11.14- ◼︎ To mark GENUONE’s third anniversary, the company invests KRW 23.8 billion in production facilities as a stepping stone toward sustainable growth ◼︎ Aims to provide a more stable supply through expansion of Sejong Plant, introduction of new large-capacity facilities, expansion of sterile IV bag production line, and replacement of facilities for oral liquid glass packaging (2023-11-14) On November 14th, GENUONE Sciences (CEO Lee Sam-soo, hereinafter GENUONE), Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization), announced that the company had decided to invest an additional KRW 23.8 billion in production facilities in the plant to increase production efficiency and growth potential. GENUONE was launched under the current new name in December 2020 after IMM Private Equity (IMM PE), a private equity fund (PEF), acquired Kolmar Korea Pharmaceutical Division and Kolmar Pharma. First generics and incrementally modified drugs (IMD) are being developed and produced based on the current, proven drug development technology and know-how, full line-up manufacturing and production facilities, and clinical licensing capabilities. Thanks to the KRW 12.5 billion investment made last year, production increased by more than 25% at the Sejong Plant and 20% at the Jecheon Plant year-on-year, and the increases are covering the demand for drugs for respiratory diseases, where needs have increased since the pandemic, and the production of major new products such as Mirabegron and Teneliptin. The investment was in line with the scheduled launch of a new diabetes complex drug, which will be a major addition to GENUONE's portfolio. In order to secure stable production and increase production efficiency in line with the increasing demand for drugs for chronic diseases, the company plans to introduce heavy-duty facilities of up to 1000kg (based on coating machines). Recently, an additional KRW 23.8 billion investment agenda was approved at the regular board meeting. This will allow the company to secure space for up to two large-capacity facility lines and expand the large-capacity facility lines within 25 years. In addition, GENUONE will be expanding the sterile IV bag production line and replacing glass packaging facilities to improve the quality of its oral liquids and the rate of cost to sales. The company decided to invest in sterile IV bag production to expand annual production by 1.5 times in line with the growth of the premix IV bag market. Premix IV bags are known to lower the risk of infection and errors in drug administration in hospitals. Investing in facilities for oral liquid glass packaging, not only cuts costs, it increases production by 3.3 times by replacing degraded facilities with new ones. GENUONE has already made an investment of KRW 12.5 billion in 2023 to upgrade its production capacity. The additional investment of KRW 23.8 billion was largely driven by IMM PE, the shareholder company, to actively innovate GENUONE’s management and improve efficiency. Based on this investment, the company will make further efforts to increase production efficiency. “GENUONE has continued to invest over the past three years to uphold its status as a global CDMO company with productivity and expertise,” said Lee Sam-soo, CEO of GENUONE. He added, “We will manufacture and supply drugs that are more stable and reliable by optimizing production through this large-scale additional investment.”
Genu Pharma Receives Minister Prize from the Minister of Employment and Labor at the “2023 Fair Recruitment Excellence Competition”
2023.11.02- ◼︎ “Fair Recruitment Excellence Competition” held to support the spread of a fair recruitment culture ◼︎ Genu Pharma receives high praise and selected as best practice in the Transparency, Ability-oriented, and Empathy categories ▲ Lee Sam-soo, CEO of GENUONE Sciences Genu Pharma (right), and Minister Lee Jung-sik of the Ministry of Employment and Labor (left) take a commemorative photo at the 2023 Fair Recruitment Excellence Competition Award Ceremony. (Image provided by GENUONE Sciences) (2023-11-02) On November 2nd, Genu Pharma, a subsidiary of Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization) company GENUONE Sciences (hereinafter GENUONE, CEO Lee Sam-soo), announced that it received the Ministerial Prize from the Minister of Employment and Labor at the 2023 Fair Recruitment Excellence Competition. The Ministry of Employment and Labor, in collaboration with the Human Resources Development Service of Korea, has been holding the Fair Recruitment Excellence Competition every year since 2016. The competition recognizes and rewards various efforts made to improve the fair recruitment process and performance practices that are employed within it. In particular, this year emphasized the commitment to aid the spread of a corporate culture based on fair recruitment practice by discovering and awarding best practices in the field in connection with the government initiative “Ensuring fair recruitment opportunities.” Genu Pharma received high praise in the▲Transparency ▲Ability-oriented ▲Empathy categories and was recognized for its best practice in fair recruitment. Using the AI competency testing program, the company conducts transparent and objective recruitment procedures, and delivers information quickly for the convenience of job seekers. In addition, the HOPE campaign helped spread the culture of in-house employment equality that has strengthened the fair recruitment process. “The talent management employed by GENUONE and Genu Pharma starts with acquiring excellent talent through fair recruitment,” said Lee Sam-soo, CEO of GENUONE, “and we will continue to realize our goal of being a global CDMO company through fair recruitment that doesn’t apply unfair discrimination amongst its job seekers.” GENUONE and Genu Pharma are striving to spread the corporate culture of employment equality through the “HOPE” campaign, named through its acronym combining the first letters of “Harmony”, “Opportunity”, “Protection of Motherhood”, and “Equity.” In May 2023, GENUONE won the Gender Equality in Employment category at the “2023 Employment Equality Contribution Award” and was awarded the Minister of Employment and Labor's Commendation. In September 2023, the company was selected as an “Excellent Company in Human Resource Development” by the Human Resources Development Service of Korea, and Genu Pharma won the “Family-Friendly Enterprise Award” awarded by Jecheon, Chungcheongbuk-do Province.
GENUONE Sciences Hosts Blood Drive to Stabilize Blood Supply
2023.10.31- ◼︎ 40 executives and employees at GENUONE donate blood to contribute to the spread of the healthy blood donation culture and to assist with the stabilization of blood supplies ▲ GENUONE Sciences employees donate blood on the bloodmobile on the 30th and takes a memorial photo. (Image provided by GENUONE Sciences) (2023-10-31)On October 31st, GENUONE Sciences (CEO Lee Sam-soo, hereinafter GENUONE), Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization), announced it hosted a blood drive with employees to assist with the stabilization of blood supplies. As the national blood supply crisis continues, GENUONE has organized group blood donations to help stabilize the supply of blood and promote a healthy donation culture. On October 30th, about 40 executives and employees voluntarily participated in the group's blood donation, which was carried out at GENUONE’s Sejong Office. An employee of GENUONE who participated in the blood donation on this day, said, “I had a vague fear of donating blood, but when I actually did it, I was surprised to see blood test results on 10 items, and it felt meaningful that this could save someone else’s life.”“As a pharmaceutical company that prioritizes national health, we have been conducting group blood donations to help overcome the national blood supply crisis,” said a GENUONE representative, “and, in the future, we will continue our social responsibility through social contribution activities that encompass many aspects of society.”
GENUONE Sciences Selected as an “Excellent Company in Human Resource Development” by the Human Resources Development Service of Korea
2023.09.20- ◼︎ Organized by the Human Resources Development Service of Korea, co-certified and organized by the Ministry of Employment and Labor, Ministry of Education, Ministry of Trade, Industry and Energy, and the Ministry of SMEs and Startups ◼︎ Spreading in-house employment equality culture and operating systematic education, GENUONE is certified as an excellent company in human resource development and management (2023-09-20)On September 20th, GENUONE Sciences (CEO Lee Sam-soo, hereinafter GENUONE), Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization), announced that the company was selected as an “2023 Excellent Company in Human Resource Development.” The Excellent Human Resource Development Certification is a project that certifies businesses recognized as fostering excellent human resource development and management, including the hiring and development of talent based on ability and offering opportunities for ongoing employee education and training. It is jointly certified and organized by four ministries, including the Ministry of Employment and Labor, the Ministry of Education, the Ministry of Industry, Trade and Resources, and the Ministry of SMEs and Startups, and is organized by the Human Resources Development Service of Korea. The certification is valid for three years, and during this period, the recipient receives various business benefits. This includes exemption from routine work supervision by the Ministry of Employment and Labor, the granting of additional points for the candidate selection of the Government Award for Vocational Skills Development, the granting of additional points for public bidding in the Public Procurement Service, and the granting of additional points in the selection of Ministry of SMEs and Startups projects. Under the leadership principle that “The growth of its employees is the growth of the company,” GENUONE runs a number of programs designed to give all workers equitable opportunity and foster positive work environments. The internal training program “GLOW (Genuone Leading Opportunities With you)” offers training to enhance work capabilities according to specific duties and positions in order to assist all members in becoming global CDMO specialists. In particular, starting this year, GENUONE is striving to spread the corporate culture of employment equality through the “HOPE” campaign, the acronym for which combines the first letters of “Harmony”, “Opportunity”, “Protection of Motherhood”, and “Equity.” In May 2023, the company was awarded a commendation from the Ministry of Employment and Labor and was certified as a Female-Friendly Company by the Ministry of Gender Equality & Family and has been continuously re-certified since 2014. CEO Lee Sam-soo stated, “GENUONE's growth strategy and management philosophy include always considering the development and management of human resources as a top priority. We will continue to strengthen our competitiveness by providing a wide range of support for employees.”
Genu Pharma receives “Family-Friendly Enterprise Award” awarded by Jecheon, Chungcheongbuk-do Province, Contributing to the Spread of Employment Equality Culture
2023.11.28- ◼︎ Recognized for creating a family-friendly working environment, including expanding female employment and introducing a variety of welfare systems ◼︎ GENUONE and Genu Pharma focus on the HOPE campaign to promote an employment equality culture to create a work-life balance ▲ Lee Sam-soo, CEO of GENUONE Sciences and Genu Pharma (second from the left), and employees takes a photo to commemorate receiving the Family-Friendly Enterprise Award (Image provided by GENUONE Sciences) (2023-09-06) On September 6th, Genu Pharma, a subsidiary of Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization) company GENUONE Sciences (hereinafter GENUONE, CEO Lee Sam-soo), announced that it had received the “Family-Friendly Enterprise Award” awarded by Jecheon, Chungcheongbuk-do Province. In celebration of the 2023 Gender Equality Week in Jecheon City, the award ceremony, organized by the Jecheon Women's Organization Council, was attended by the Mayor of Jecheon Kim Chang-kyu, GENUONE CEO Lee Sam-soo, Director Ok Kwang-hee, and Factory Director of Genu Pharma Kim Yoon-kwan, as well as a number of related business officials. Genu Pharma, located in Jecheon City, Chungcheongbuk-do Province, was awarded the Jecheon City's “Family-Friendly Enterprise Award” in recognition of its contribution to ▲creating quality jobs and expanding female employment, ▲realizing a happy workplace through the introduction of various welfare systems, and ▲creating a working environment that is considerate of its employees. Under the management philosophy that the growth of members is the growth of the company, GENUONE and Genu Pharma operate various systems to foster an atmosphere where workers' well-being is given first priority and where they are free to reach their full potential. Starting this year, GENUONE is striving to spread the corporate culture of employment equality through the “HOPE” campaign, under the banner acronym derived by combining the first letters of “Harmony”, “Opportunity”, “Protection of Motherhood”, and “Equity.” With these efforts, GENUONE won the Gender Equality in Employment category at the “2023 Employment Equality Contribution Awards” and was awarded the Minister of Employment and Labor's Commendation in May 2023. In addition, GENUONE was certified as a Female-Friendly Company by the Ministry of Gender Equality & Family and has been continuously re-certified since 2014. “The compatibility of work and family life is becoming more important in our society,” said Lee Sam-soo, CEO of GENUONE and Genu Pharma, “and we will continue to contribute to the pharmaceutical industry and the economic development of our country by promoting a sustainable in-house culture as well as establishing a system that fosters work-life balance”.
GENUONE Sciences Conducts Remote Outreach Activities for Marginalized Children
2023.08.31- ◼︎ 100 GENUONE employees join forces with Social Welfare Foundation Eastern Social Welfare Society in “Two+ Gather” Campaign ◼︎ CEO Lee Sam-soo aims to “continue to promote social contribution activities for communities in need of help and practice genuine ESG management” ▲ GENUONE Sciences employees record a commemorative photo after attending the remote outreach work (From left, Managing Director Shim Jung-sup of the Quality Division, Executive Director Byun Hyung-won of the Production Division, Director Song Kyung-sang of Quality Group 1) (2023-08-31)On August 31st, GENUONE Sciences (hereinafter GENUONE) CEO Lee Sam-soo, Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization), stated that they have conducted volunteer activities with executives and employees to provide basic care products for marginalized children living in social blind spots. The outreach program was conducted in line with the “Two+ Gather Campaign” of the Eastern Social Welfare Society (Chairman Kim Jin-sook), a social welfare corporation. A total of 100 employees from the GENUONE Head Office, Central Research Institute, Sejong Office, and Jecheon Office participated in the event. “Two+ Gather Campaign” is a participatory campaign in which the Eastern Social Welfare Society provides basic care items such as bibs and handkerchiefs for marginalized children. Established in 1972, the Eastern Social Welfare Society provides comprehensive welfare services to underprivileged neighbors around us, such as children, single mothers, youth, disabled people, and the elderly. GENUONE employees who participated in the event hand-crafted a total of 200 “Delicious Meal Bib” kits and delivered them to the Eastern Social Welfare Society. The cost of purchasing the kit will be used to fund marginalized children, to provide meals, medical care, education, baby supplies, etc. Also, the completed bibs will be provided to children's facilities, community houses for single Mothers and children, and related institutions. (Please see note) “We are glad to help babies who need care and attention through this remote outreach event in a small way,” said Executive Director Byun Hyung-won of the GENUONE Production Division, “and we plan to actively participate in the event in the future.”“Thanks to the voluntary participation of many employees to help the marginalized children, we have been able to help children through this remote event,” said Lee Sam-soo, CEO of GENUONE “and in the future, GENUONE plans to carry out a variety of social contribution activities and develop a genuine ESG management to spread love to communities in need.” In addition, last year GENUONE conducted outreach activities to improve awareness and promote the rights of children with disabilities, has built an ESG roadmap for sustainable growth, and has conducted reliable management activities.
GENUONE Sciences Hosts Tour Program of the Central Research Institute for the Second Half of 2023
2023.08.25- ◼︎ On August 24th, the Central Research Institute Tour Program was conducted for job seekers in the field of pharmaceutical research ◼︎ Met with seniors to discuss job-related questions, and took lectures on the prospects of the pharmaceutical industry and tour of actual labs ◼︎ Central Research Institute tour receives positive responses from participants, with several past participants joining GENUONE (2023-08-25) On August 25th, GENUONE Sciences (hereinafter GENUONE) CEO Lee Sam-soo, Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization), stated that it had organized a “Central Research Institute Tour” program for those looking to work as pharmaceutical researchers. GENUONE has been running a tour program of the Central Research Institute since last year to provide customized information for Korean students majoring in pharmaceutical-related studies and undergraduate and graduate students in pharmaceutical universities and to recruit excellent pharmaceutical talent. The Central Research Institute tour took place on August 24th 2023, and a total of 27 people were selected through recommendations from current Central Research Institute researchers, professors from pharmaceutical-related departments, and pharmaceutical universities. The “Central Research Institute Tour” began with an introduction of GENUONE, an overlook at the present and future of the pharmaceutical and CDMO industries, a tour of the analysis and formulation laboratories used by actual researchers, and finally a tour of the research work being carried out using the latest equipment. During the “Meeting with Seniors” session, the attendees had a meaningful time where researchers shared their pharmaceutical job expertise and attitude, as well as know-how involved in job applications. In particular, CEO Lee Sam-soo and Director Oh Joon-kyo of the Central Research Institute shared prospects related to the pharmaceutical industry and the competitiveness of the Central Research Institute, which drew the attention of job seekers. The students who attended the program said, “It was nice to hear from the CEO himself and the Director of the Institute and get a glimpse of the future and growth potential of the pharmaceutical industry,” and “I had a meaningful time meeting researchers who are currently engaged in the field I am interested in, and to tour the research environment.” GENUONE's Central Research Institute Tour has received a positive response from participants with its practical approach and in-depth lectures on the job. In fact, some of the participants who attended the tour program last year applied, and are currently working at GENUONE Headquarters and Central Research Institute. “We are delighted to meet bright talent who will play a leading role in the pharmaceutical industry in the future through this tour,” said GENUONE CEO Lee Sam-soo, “and we will continue to host educational and experience programs that will help the growth and success of job seekers in the future.”
GENUONE Sciences Holds Company-wide Training to Cultivate Sustainable Management
2023.08.18- ◼︎ GENUONE conducts sustainability management training for employees above the team leader position and plans to expand it into company-wide training in the future ▲GENUONE Sciences is conducting ESG and compliance training for all employees above the Team Leader position. (Image provided by GENUONE Sciences) (2023-08-18) On August 18th, GENUONE Sciences (CEO Lee Sam-soo, hereinafter GENUONE), Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization), announced that it has conducted in-house training to foster a sustainable management mindset within executives and employees. Ok Kwang-hee, Director of GENUONE Management Support and Head of Sustainability Management, gave the lecture for this training which was conducted for all employees above the Team Leader position. The talk began with an overview of sustainability management and then covered how to implement it in the real world. The employees who participated in this training said, “It was meaningful to realize the significance of sustainability management through relevant terms and case-based training” and “We will actively participate in GENUONE’s sustainability management in the future by working with our team members on ESG initiatives that can be practiced in a GENUONE way.” Since its founding in 2021, GENUONE has been implementing sustainable management in line with its objective of “Creating Healthier Tomorrows.” In addition, the company publishes a sustainability report every year, sharing GENUONE's philosophy, goals, execution systems, detailed activities, and achievements. “GENUONE seeks to demonstrate results and further contribute to society by applying sustainable management to our actual work, not just as a formality,” said Lee Sam-soo, CEO of GENUONE. “We will gradually expand education related to sustainable management for all executives and employees to make this an integral part of GENUONE culture.”
GENUONE Sciences Targets Southeast Asia with its antipeptic ulcer drug called "Munals Suspension"
2023.07.26- ※ This information is not being used to promote the product commercially (Philippines product name : Algina suspension / Kremil-S suspension Vietnam product name: Alfogine suspension). The product is a general drug. When writing the article, please make sure it does not violate the Pharmaceutical Affairs Act. The basic information about the permits and goods supplied as reference materials should only be used as a guide when writing the article. For more information, please refer to the Ministry of Food and Drug Safety website. ◼︎ Munals Suspension establishes itself as a representative product of GENUONE, generating 3 billion won in annual sales and exporting to a total of four countries ◼︎ About 20 million pouches are exported to the Philippines annually, with local marketing to be expanded and 100 million pouches delivered by 2025 ◼︎ Registered as a first generic in Vietnam on July 14th, with facility investment in Sejong Plant supporting its smooth production ▲ 'Munals Suspension (Local product name in the Philippines: Algina Suspension - produced by GENUONE Sciences (Image provided by GENUONE Sciences) (2023-07-26)GENUONE Sciences (CEO Lee Sam-soo, hereinafter GENUONE), Korea's leading synthetic drug CDMO (Contract Development Manufacturing Organization), is targeting the Southeast Asian market with its antipeptic ulcer drug called "Munals Suspension". The Munals Suspension from GENUONE is a generic medication that comes in stick pack pouches and contains sodium alginate, sodium bicarbonate, and calcium carbonate. It improves gastroesophageal reflux symptoms such as acid reflux, heartburn, and indigestion due to the reflux of stomach contents. GENUONE currently exports Munals Suspension to a total of four countries. In particular, for the Philippines and Vietnam, it is the largest export scale amongst domestic pharmaceutical businesses, in terms of generic products with the same ingredients. Munals Suspension is registered and sold as a first generic in the Philippines, and about 20 million pouches are exported each year through a partnership with Unilab, Southeast Asia's top pharmaceutical company. Exports of Munals Suspension are anticipated to surpass 100 million pouches by 2025 as marketing efforts in the Philippines continue. It was also registered as a first generic on July 14th in Vietnam, where it will be made available in the fourth quarter and will continue to be actively marketed. GENUONE is also investing about 20 billion won in infrastructure at the Sejong plant over three years to continue its seamless export program in the future. In addition, the company exports Munals Suspension to Mongolia and Cambodia and has recently signed supply contracts with Malaysia and Thailand, continuing to actively target Southeast Asian markets. "The Munals Suspension is one of GENUONE's representative products with annual sales of 3 billion won," stated Lee Sam-soo, CEO of GENUONE. "Based on the ongoing facility investment of 20 billion won, we will reinforce our position as a global CDMO company."
Locations
View detailCareers
View detail
- ABOUT US
- OUR PRODUCTS
- CAREERS
- NEWSROOM
Copyright ⓒ 2021 GENUONE Sciences Inc. All rights Reserved.